Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.

Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, Roederer M, Koup RA, Goudsmit J, Jahrling PB, Nabel GJ.

PLoS Med. 2006 Jun;3(6):e177. Epub 2006 May 16.

2.

Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.

Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, Deitz SB, Yu H, Swain BM, Moore KM, Pratt WD, Hart MK, Dong JY.

J Virol. 2006 Mar;80(6):2738-46.

3.

Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.

Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, Dye JM, Holman DH, Dong JY.

Clin Vaccine Immunol. 2010 Apr;17(4):572-81. doi: 10.1128/CVI.00467-09. Epub 2010 Feb 24.

4.

Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.

Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, Scott DP, Geisbert TW, Kawaoka Y, Katze MG, Feldmann H, Messaoudi I.

Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893-8. doi: 10.1073/pnas.1209591110. Epub 2013 Jan 14.

5.

A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection.

Choi JH, Jonsson-Schmunk K, Qiu X, Shedlock DJ, Strong J, Xu JX, Michie KL, Audet J, Fernando L, Myers MJ, Weiner D, Bajrovic I, Tran LQ, Wong G, Bello A, Kobinger GP, Schafer SC, Croyle MA.

Mol Pharm. 2015 Aug 3;12(8):2712-31. doi: 10.1021/mp500646d. Epub 2014 Nov 14.

6.

A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.

Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, Murphy BR, Collins PL, Sanchez A.

J Virol. 2006 Mar;80(5):2267-79.

7.

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.

Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ.

Nature. 2003 Aug 7;424(6949):681-4.

PMID:
12904795
8.

Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.

Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, Olinger GG, Groebner JL, Lee JS, Pratt WD, Custer M, Kamrud KI, Smith JF, Hart MK, Dye JM.

J Virol. 2013 May;87(9):4952-64. doi: 10.1128/JVI.03361-12. Epub 2013 Feb 13.

9.

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS; VRC 205 Study Team..

Vaccine. 2010 Dec 16;29(2):304-13. doi: 10.1016/j.vaccine.2010.10.037. Epub 2010 Oct 27.

PMID:
21034824
10.

CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates.

Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, Reimann KA, Bao S, Rao S, Roederer M, Jahrling PB, Koup RA, Nabel GJ.

Nat Med. 2011 Aug 21;17(9):1128-31. doi: 10.1038/nm.2447.

PMID:
21857654
11.

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.

Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, Custers J, Vellinga J, Hendriks J, Jahrling P, Roederer M, Goudsmit J, Koup R, Sullivan NJ.

J Virol. 2011 May;85(9):4222-33. doi: 10.1128/JVI.02407-10. Epub 2011 Feb 16.

12.

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.

Richardson JS, Yao MK, Tran KN, Croyle MA, Strong JE, Feldmann H, Kobinger GP.

PLoS One. 2009;4(4):e5308. doi: 10.1371/journal.pone.0005308. Epub 2009 Apr 23.

13.

Successful topical respiratory tract immunization of primates against Ebola virus.

Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, Murphy BR, Collins PL, Sanchez A.

J Virol. 2007 Jun;81(12):6379-88. Epub 2007 Apr 11.

14.

A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.

Tsuda Y, Caposio P, Parkins CJ, Botto S, Messaoudi I, Cicin-Sain L, Feldmann H, Jarvis MA.

PLoS Negl Trop Dis. 2011 Aug;5(8):e1275. doi: 10.1371/journal.pntd.0001275. Epub 2011 Aug 9.

15.

Development of a preventive vaccine for Ebola virus infection in primates.

Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ.

Nature. 2000 Nov 30;408(6812):605-9.

PMID:
11117750
16.

Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.

Dowling W, Thompson E, Badger C, Mellquist JL, Garrison AR, Smith JM, Paragas J, Hogan RJ, Schmaljohn C.

J Virol. 2007 Feb;81(4):1821-37. Epub 2006 Dec 6.

17.

Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.

Richardson JS, Pillet S, Bello AJ, Kobinger GP.

J Virol. 2013 Apr;87(7):3668-77. doi: 10.1128/JVI.02864-12. Epub 2013 Jan 9.

18.

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.

Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel GJ, Graham BS.

Clin Vaccine Immunol. 2006 Nov;13(11):1267-77. Epub 2006 Sep 20.

19.

Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus.

Wong G, Qiu X.

Methods Mol Biol. 2016;1403:245-57. doi: 10.1007/978-1-4939-3387-7_12.

PMID:
27076134
20.

Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.

Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, Stanley D, Fabozzi G, Nichol ST, Ksiazek TG, Rollin PE, Wahl-Jensen V, Bailey M, Jahrling PB, Roederer M, Koup RA, Sullivan NJ.

PLoS Pathog. 2010 May 20;6(5):e1000904. doi: 10.1371/journal.ppat.1000904.

Supplemental Content

Support Center